Brief: Rigel Announces U.S. FDA Approval Of Acute Myeloid Leukemia Drug Rezlidhia™ (Olutasidenib)
01/12/2022 22:20
Dec 1 (Reuters) - Rigel Pharmaceuticals Inc RIGL.O :
* RIGEL ANNOUNCES U.S. FDA APPROVAL OF REZLIDHIA™
(OLUTASIDENIB)
FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY
ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE IDH1 MUTATION
Source text for Eikon: ID:nPn2SlV7xa
Further company coverage: RIGL.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)